Core Insights - C3.ai has experienced a significant decline in stock value, dropping 50% in 2025, with a notable loss of over 25% in a single day following the announcement of preliminary fiscal Q1 results [1][2] - The company's preliminary revenue for the last quarter was just over $70 million, falling short of the guidance range of $100 million to $109 million, and the non-GAAP operating loss was nearly $58 million, more than double the initial expectation [5][6] - C3.ai's performance has deteriorated compared to the previous year, where it reported $87 million in revenue and a non-GAAP operating loss of $16.6 million [6] Company Performance - C3.ai provides an AI software platform for enterprise and federal customers, and has been expanding its customer base, indicating potential in the enterprise AI software market [4] - The recent poor performance is attributed to organizational restructuring and leadership changes, which have had a disruptive effect on operations [8][9] - The CEO's health issues have also impacted the sales process, contributing to the company's underperformance [8] Future Outlook - C3.ai is currently searching for a new CEO, which may further affect its performance during the transition period [9] - The company has announced a new contract with Brazil's Eletrobras and launched new AI solutions, which could stabilize its operations in the future [11] - Despite the challenges, the AI software market is projected to grow at a compound annual rate of 25% through 2030, presenting potential opportunities for C3.ai if it can navigate its current issues effectively [13]

Group 1 - The C3.ai class action lawsuit, titled Liggett v. C3.ai, Inc., seeks to represent purchasers of C3.ai securities and alleges violations of the Securities Exchange Act of 1934 by C3.ai and its executives [1] - The lawsuit claims that C3.ai misrepresented its revenue outlook and growth potential while downplaying risks associated with CEO Thomas M. Siebel's health [4] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 FY 2026 and reduced its revenue guidance for the full fiscal year, leading to a stock price drop of over 25% [5] Group 2 - The lead plaintiff process allows any investor who purchased C3.ai securities during the Class Period to seek appointment as lead plaintiff, representing the interests of the class [6] - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]

Core Viewpoint - A securities class action lawsuit has been filed against C3.ai, Inc. for failing to disclose material information during the class period, leading to significant financial losses for investors [3][4]. Group 1: Lawsuit Details - Investors have until October 21, 2025, to file lead plaintiff applications in the lawsuit against C3.ai, Inc. for securities purchased between February 26, 2025, and August 8, 2025 [1][2]. - The lawsuit alleges that C3 and certain executives violated federal securities laws by not disclosing critical information during the class period [3]. - On August 8, 2025, C3 disclosed disappointing preliminary financial results for Q1 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing the poor performance to a reorganization and health issues of the CEO [3]. Group 2: Financial Impact - Following the announcement of the disappointing results, C3's share price dropped from $22.13 on August 8, 2025, to $16.47 on August 11, 2025, marking a decline of approximately 25.58% [4]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent securities litigation law firm, is representing the investors in this case, with a strong track record in recovering investment losses due to corporate fraud [4].

Core Insights - C3.ai, Inc. is emphasizing its partner ecosystem as a crucial growth driver, with 73% of agreements in fiscal 2025 completed through partnerships, marking a 68% increase from the previous year [1][9] - The company reported a significant rise in partner-supported bookings, which surged 419% year over year in the fiscal fourth quarter, with 59 agreements signed through collaborations [1] Partnerships and Collaborations - The partnership with Microsoft is pivotal, resulting in 28 new agreements in the fiscal fourth quarter, particularly in manufacturing and chemicals [2] - Collaborations with Google Cloud and Amazon's AWS are also enhancing market reach and delivery capabilities [2] - New advisory alliances with McKinsey QuantumBlack and PwC are broadening distribution capacity and targeting key industries [3][4] Market Performance and Valuation - C3.ai shares have declined by 25.8% over the past year, compared to a 9.5% decline in the industry [7] - The company trades at a forward price-to-sales ratio of 5.58X, significantly lower than the industry average of 17.49X [8] - The Zacks Consensus Estimate for fiscal 2026 earnings per share indicates a year-over-year decline of 239%, while fiscal 2027 shows a projected increase of 65.9% [11]

Group 1 - A class action lawsuit has been filed against C3.ai, Inc. on behalf of investors who purchased shares between February 26, 2025, and August 8, 2025 [1][2] - C3.ai is an artificial intelligence technology company based in Redwood City, California, providing scalable enterprise AI applications for various sectors [2] - On August 8, 2025, C3.ai reported weak preliminary financial results for Q1 FY2026 and lowered its full-year revenue guidance, citing leadership changes and the CEO's health as contributing factors [3] Group 2 - Following the announcement of the weak financial results, C3.ai's stock price fell from $22.13 to $16.47, representing a one-day loss of over 25% [3]

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. concerning allegations of securities fraud and unlawful business practices by the company and its officers [2][3]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline of October 21, 2025, to apply as Lead Plaintiff if they purchased C3 securities during the Class Period [3]. - The lawsuit follows C3's announcement of disappointing preliminary financial results for Q1 of fiscal 2026 and a reduction in revenue guidance for the full fiscal year 2026, attributed to a reorganization with new leadership and health issues of the CEO [3]. Group 2: Stock Market Reaction - Following the negative news, C3's stock price dropped by $5.66 per share, representing a decline of 25.58%, closing at $16.47 per share on August 11, 2025 [4].

Core Viewpoint - The C3.ai class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly in relation to the health of CEO Thomas M. Siebel, leading to significant stock price declines following disappointing financial results [1][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Liggett v. C3.ai, Inc., seeks to represent purchasers of C3.ai securities and claims violations of the Securities Exchange Act of 1934 [1][3]. - The lawsuit alleges that C3.ai's optimistic growth reports were misleading and overly reliant on the CEO's health, which was not disclosed adequately to investors [4][5]. - Following the announcement of disappointing preliminary financial results for Q1 FY 2026 and a reduction in revenue guidance, C3.ai's stock price fell by more than 25% [5]. Group 2: Legal Process - Investors who suffered losses can apply to be the lead plaintiff in the class action lawsuit, with the deadline for motions set for October 21, 2025 [2][6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Group 3: Company Background - C3.ai operates as an enterprise artificial intelligence application software company [3].

Core Viewpoint - A securities class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors by making overly positive statements while concealing material adverse facts [2][6]. Allegations - The lawsuit claims that C3.ai and its executives misled investors regarding the company's performance and potential [2]. - The CEO's health issues significantly hindered the company's ability to close deals, and management failed to minimize the impact of these health issues on operations [6]. Triggering Event - On August 8, 2025, C3.ai announced disappointing preliminary Q1 FY2026 results and cut full-year revenue guidance, attributing weak sales to "reorganization with new leadership" and the CEO's health problems [6]. Stock Impact - Following the announcement on August 8, 2025, C3.ai's stock closed at $22.13 per share and fell to $16.47 per share by August 11, 2025, representing a drop of approximately 25.6% in a single trading day [6]. Next Steps for Investors - Investors who suffered losses can seek appointment as lead plaintiff prior to October 21, 2025, by contacting Wolf Haldenstein [2][6].

Core Viewpoint - A class action securities lawsuit has been filed against C3.ai, Inc. due to alleged securities fraud that negatively impacted investors between February 26, 2025, and August 8, 2025 [1][2] Company Performance - The lawsuit claims that C3.ai's management provided overly positive statements while concealing significant adverse facts about the company's growth, particularly the health issues of its CEO, which affected deal closures [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health problems [2] - Following the announcement, C3.ai's stock price plummeted from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [2] Legal Proceedings - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request to be appointed as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors about the impact of its CEO's health on the company's business prospects [1][2]. Group 1: Allegations and Impact - The lawsuit claims that C3.ai failed to disclose how the CEO's health affected the company's ability to close deals and that management was ineffective in mitigating this impact [2]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing the poor performance to "the reorganization with new leadership" and the CEO's health issues [3]. - Following this announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of over 25% [3]. Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs in the class action must submit their papers to the court by October 21, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP, the firm handling the case, has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].